Aligos Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
The conference highlighted a robust pipeline, with pevi showing unprecedented HBV DNA and antigen suppression, no resistance, and a strong safety profile. ALG-009 demonstrated superior efficacy in MASH and potential synergy with incretins. Key milestones are expected in 2024 and 2027.
-
The conference highlighted advances in HBV and MASH therapies, focusing on pevi's superior viral suppression, dual mechanisms, and regulatory progress. Pevi is positioned as a future standard for chronic suppression and as a backbone for functional cure regimens, while ALG-055009 shows promise for MASH and obesity.
-
ALG-000184 shows unprecedented efficacy and safety in HBV, with no resistance and strong DNA/antigen suppression, positioning it as a new standard for chronic suppression and a backbone for cure regimens. ALG-055009 demonstrates promise in MASH, with key data and partnerships expected soon.
-
A new capsid assembly modulator for hepatitis B is entering phase II, showing superior viral suppression and antigen reduction compared to standard therapies, with strong regulatory support and significant commercial potential. Key milestones include imminent study initiation and major data readouts through 2027.
Fiscal Year 2024
-
The company is advancing a pipeline targeting hepatitis B, MASH, and COVID, with CAM-E showing superior viral suppression and durability in phase 1. Upcoming milestones include a phase 2 hepatitis B trial, MASH phase 2b, and a ritonavir-free COVID program, supported by strong cash reserves.
-
A novel hepatitis B therapy is advancing to a global phase 2 study, showing superior efficacy and no resistance, with broad regulatory support and a market potential above $2 billion. The company is also progressing a promising THR beta asset and expects major catalysts in 2025.
-
ALG-00184, a potent capsid assembly modulator, shows superior viral suppression and no resistance in HBV patients, outperforming current standards in both E-antigen positive and negative groups. The regulatory strategy targets chronic suppression for broad patient benefit, with phase II trials set to begin soon.
-
Top-line results from a Phase 2B study of ALG-055009 in MASH showed robust, statistically significant liver fat reduction and favorable safety at multiple doses, outperforming an approved competitor. The drug also improved key lipid biomarkers and demonstrated a differentiated tolerability profile.